Mydecine Innovations Group 将来の成長

Future 基準チェック /06

現在、 Mydecine Innovations Groupの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

n/a

収益成長率

n/a

EPS成長率

Pharmaceuticals 収益成長	23.9%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	None
最終更新日	n/a

今後の成長に関する最新情報

更新なし

Recent updates

このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Mydecine Innovations Group は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。

シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。

業績と収益の成長予測

OTCPK:MYCO.F - アナリストの将来予測と過去の財務データ ( )CAD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
9/30/2024	N/A	-12	0	0	N/A
6/30/2024	N/A	-12	0	0	N/A
3/31/2024	N/A	-11	-1	-1	N/A
12/31/2023	N/A	-21	-4	-4	N/A
9/30/2023	N/A	-19	-5	-5	N/A
6/30/2023	N/A	-20	-7	-7	N/A
3/31/2023	N/A	-21	-10	-10	N/A
12/31/2022	N/A	-16	-8	-8	N/A
9/30/2022	0	-23	-12	-12	N/A
6/30/2022	0	-18	-16	-17	N/A
3/31/2022	0	-24	-17	-17	N/A
12/31/2021	0	-24	-24	-24	N/A
9/30/2021	0	-19	-23	-23	N/A
6/30/2021	0	-37	-18	-17	N/A
3/31/2021	0	-32	-17	-16	N/A
12/31/2020	0	-27	-8	-7	N/A
9/30/2020	0	-39	-5	-4	N/A
6/30/2020	0	-23	-4	-4	N/A
3/31/2020	0	-20	-1	-1	N/A
12/31/2019	0	-21	-1	-1	N/A
9/30/2019	0	-5	-1	-1	N/A
6/30/2019	0	-5	-2	-2	N/A
3/31/2019	0	-11	-4	-4	N/A
12/31/2018	0	-13	-4	-4	N/A
9/30/2018	0	-22	-7	-7	N/A
6/30/2018	0	-21	N/A	-6	N/A
3/31/2018	0	-18	N/A	-5	N/A
12/31/2017	N/A	-18	N/A	-5	N/A
9/30/2017	N/A	-14	N/A	-4	N/A
6/30/2017	N/A	-14	N/A	-4	N/A
3/31/2017	N/A	-11	N/A	-3	N/A
12/31/2016	N/A	-8	N/A	-1	N/A
9/30/2016	0	-1	N/A	0	N/A
6/30/2016	0	-1	N/A	0	N/A
3/31/2016	0	-3	N/A	-1	N/A
12/31/2015	N/A	-4	N/A	-1	N/A
9/30/2015	0	-4	N/A	-1	N/A
6/30/2015	0	-4	N/A	-1	N/A
3/31/2015	0	-2	N/A	0	N/A
12/31/2014	0	-1	N/A	0	N/A
9/30/2014	0	-1	N/A	0	N/A
3/31/2014	0	0	N/A	0	N/A
12/31/2013	0	0	N/A	0	N/A

アナリストによる今後の成長予測

収入対貯蓄率: MYCO.Fの予測収益成長が貯蓄率 ( 2.6% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: MYCO.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: MYCO.Fの収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: MYCO.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: MYCO.Fの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: MYCO.Fの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Mydecine Innovations Group 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

Mydecine Innovations Group Inc., Annual General Meeting, Jul 05, 2024

Mydecine Innovations Group Inc. announced that it expects to receive CAD 1 million in funding

Mydecine Innovations Group Inc Announces Resignation of Neil Stevenson-Moore as Director

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 1.104 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 3.75 million.

Mydecine Innovations Group Inc. Appoints John Ross as Corporate Secretary

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Mydecine Innovations Group Inc., Annual General Meeting, Apr 20, 2023

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 5 million.

Pangenomic Health Inc. (CNSX:NARA) completed the acquisition of Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F).

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 4.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering in the amount of CAD 0.5 million.

Mydecine Innovations Group Inc. Announces Appointment of John Ross as Its Chief Financial Officer

Mydecine Innovations Group Inc. has completed a Follow-on Equity Offering.

Pangenomic Health Inc. (CNSX:NARA) signed an arm's length non binding Letter of Intent to acquire Mindleap Health Inc. from Mydecine Innovations Group Inc. (OTCPK:MYCO.F) for CAD 4 million.

Mydecine Innovations Group Inc. Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces CFO Changes

Mydecine Innovations Group Inc. Announces Resignation of Directors

Mydecine Files Full Patent Application Covering Myco-006 Family of Novel Short-Acting Mdma Analogs

Mydecine Innovations Group Announces U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation

Mydecine Innovations Group Inc. Announces Board Changes

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 4 million.

Mydecine Innovations Group Inc. has completed a Composite Units Offering.

Mydecine Innovations Group Inc., Annual General Meeting, May 26, 2022

Mydecine Innovations Group Inc. Reports Positive Pre-IND Meeting with FDA for MYCO-001 Smoking Cessation Study

Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules

Mydecine Innovations Group Inc. to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic- Assisted Psychotherapy for Patients

Mydecine Innovations Group Inc. Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial

Mydecine Innovations Group Inc. Achieves Innovative Supercomputing Artificial Intelligence Modeling in Psychedelic Drug Development Enabling Quick Screening of Billions of Compounds

Mydecine Innovations Group Inc. announced that it expects to receive CAD 5.5 million in funding

Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs

Mydecine Innovations Group Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

Mydecine Provides Business Update

Mydecine Innovations Group Expands Portfolio of Novel Molecules Filing New Patent for MDMA-Like Compounds

Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004

Mydecine Unveils Artificial Intelligence Drug Discovery Program

Mydecine Innovations Group Discovers over 40 Groundbreaking Potential Pharmacologically Active Novel Compounds in Mushrooms

Health Canada Approves Expansion of Mydecine's Cultivation Capabilities for Psilocybin Producing Mushrooms

Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms

Mydecine Innovations Group Announces Management Changes

Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies Its Clinical and Commercial Supply Chain

Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta

Mydecine Innovations Group Inc. has completed a Composite Units Offering in the amount of CAD 15 million.

Mydecine Innovations Group Announces Management Changes

Mydecine Innovations Group Appoints Gordon Neal to Board of Directors

Mydecine Innovations Group Announces the Filing of Seven Provisional Patent Applications with the United States Patent and Trademark Office

Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials

Mydecine Innovations Group Launches Mindleap app

Mydecine Innovations Group Inc. Announces Appointment of Rakesh Jetly as Chief Medical Officer

Mydecine Innovations Group Inc. (CNSX:MYCO) completed the acquisition of NeuroPharm Inc.

NewLeaf Brands Inc. (CNSX:NLB) completed the acquisition of Mindleap Health.

Mydecine Innovations Group Inc. announced that it has received CAD 2.4 million in funding

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘